5-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-2-one | 1334712-67-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-2-one
• 英文别名: 5-[1-(4-Methylphenyl)pyrazolo[3,4-c]pyridin-3-yl]piperidin-2-one
• CAS: 1334712-67-2
• 化学式: C₁₈H₁₈N₄O
• 分子量: 306.367
• InChiKey: GECUIQYVUARPQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  59.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] VAP-1 INHIBITORS FOR TREATING PAIN<br/>[FR] INHIBITEURS DE VAP-1 POUR LE TRAITEMENT DE LA DOULEUR
  申请人：PROXIMAGEN LTD

  公开号：WO2017098236A1

  公开（公告）日：2017-06-15

  This invention relates to the use of inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, for the treatment of pain; and to a combined preparation comprising an inhibitor of VAP-1/SSAO activity and a steroid, and the use of the combined preparation in medicine, particularly for treatment of pain.

  这项发明涉及使用VAP-1/SSAO活性抑制剂以及包含相同成分的药物组合物，用于治疗疼痛；以及包含VAP-1/SSAO活性抑制剂和类固醇的联合制剂，以及在医学中使用该联合制剂，特别是用于治疗疼痛。
• New Enzyme Inhibitor Compounds
  申请人：Evans David

  公开号：US20130102587A1

  公开（公告）日：2013-04-25

  Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumour growth.

  揭示了抑制SSAO酶活性的化合物。还披露了包含这些化合物的药物组合物，以及在治疗或预防抑制SSAO活性有益的医疗状况中使用这些化合物，如炎症性疾病、免疫紊乱和抑制肿瘤生长。
• INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE
  申请人：Proximagen Limited

  公开号：EP2547677B1

  公开（公告）日：2015-05-06
• VAP-1 INHIBITORS FOR TREATING PAIN
  申请人：Benevolentai Cambridge Limited

  公开号：EP3386494A1

  公开（公告）日：2018-10-17
• NEW THERAPEUTIC USES OF ENZYME INHIBITORS
  申请人：PROXIMAGEN LIMITED

  公开号：US20160113893A1

  公开（公告）日：2016-04-28

  The invention relates to use of compounds which inhibit VAP-1/SSAO activity for the treatment of muscular dystrophy.